Quoin Pharmaceuticals (QNRX) Competitors $0.63 +0.00 (+0.64%) (As of 01:51 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends QNRX vs. LYRA, QTI, PAVM, PETV, LUCY, ICU, STRR, TTOO, PXDT, and NUROShould you be buying Quoin Pharmaceuticals stock or one of its competitors? The main competitors of Quoin Pharmaceuticals include Lyra Therapeutics (LYRA), QT Imaging (QTI), PAVmed (PAVM), PetVivo (PETV), Innovative Eyewear (LUCY), SeaStar Medical (ICU), Star Equity (STRR), T2 Biosystems (TTOO), Pixie Dust Technologies (PXDT), and NeuroMetrix (NURO). These companies are all part of the "medical equipment" industry. Quoin Pharmaceuticals vs. Lyra Therapeutics QT Imaging PAVmed PetVivo Innovative Eyewear SeaStar Medical Star Equity T2 Biosystems Pixie Dust Technologies NeuroMetrix Lyra Therapeutics (NASDAQ:LYRA) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, community ranking, valuation, risk, dividends, media sentiment and earnings. Do insiders and institutionals hold more shares of LYRA or QNRX? 95.6% of Lyra Therapeutics shares are held by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are held by institutional investors. 4.7% of Lyra Therapeutics shares are held by insiders. Comparatively, 3.7% of Quoin Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, LYRA or QNRX? Lyra Therapeutics has a beta of -0.04, meaning that its share price is 104% less volatile than the S&P 500. Comparatively, Quoin Pharmaceuticals has a beta of 1.85, meaning that its share price is 85% more volatile than the S&P 500. Do analysts recommend LYRA or QNRX? Lyra Therapeutics currently has a consensus target price of $4.50, indicating a potential upside of 2,305.13%. Quoin Pharmaceuticals has a consensus target price of $4.00, indicating a potential upside of 535.32%. Given Lyra Therapeutics' higher probable upside, analysts plainly believe Lyra Therapeutics is more favorable than Quoin Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lyra Therapeutics 1 Sell rating(s) 4 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00Quoin Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the media refer more to LYRA or QNRX? In the previous week, Lyra Therapeutics had 8 more articles in the media than Quoin Pharmaceuticals. MarketBeat recorded 10 mentions for Lyra Therapeutics and 2 mentions for Quoin Pharmaceuticals. Lyra Therapeutics' average media sentiment score of 0.46 beat Quoin Pharmaceuticals' score of -1.00 indicating that Lyra Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Lyra Therapeutics Neutral Quoin Pharmaceuticals Negative Is LYRA or QNRX more profitable? Quoin Pharmaceuticals has a net margin of 0.00% compared to Lyra Therapeutics' net margin of -6,635.76%. Lyra Therapeutics' return on equity of -125.07% beat Quoin Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Lyra Therapeutics-6,635.76% -125.07% -59.74% Quoin Pharmaceuticals N/A -125.60%-64.77% Which has preferable earnings & valuation, LYRA or QNRX? Quoin Pharmaceuticals has lower revenue, but higher earnings than Lyra Therapeutics. Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than Lyra Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLyra Therapeutics$1.56M7.85-$62.68M-$1.49-0.13Quoin PharmaceuticalsN/AN/A-$8.69M-$4.05-0.16 Does the MarketBeat Community favor LYRA or QNRX? Lyra Therapeutics received 19 more outperform votes than Quoin Pharmaceuticals when rated by MarketBeat users. Likewise, 60.00% of users gave Lyra Therapeutics an outperform vote while only 55.56% of users gave Quoin Pharmaceuticals an outperform vote. CompanyUnderperformOutperformLyra TherapeuticsOutperform Votes2460.00% Underperform Votes1640.00% Quoin PharmaceuticalsOutperform Votes555.56% Underperform Votes444.44% SummaryLyra Therapeutics beats Quoin Pharmaceuticals on 12 of the 16 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get Quoin Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for QNRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QNRX vs. The Competition Export to ExcelMetricQuoin PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.16M$6.45B$5.06B$8.82BDividend YieldN/A8.11%5.18%4.07%P/E Ratio-0.1510.78126.3117.81Price / SalesN/A243.711,178.7474.57Price / CashN/A22.1633.8632.53Price / Book0.115.474.684.68Net Income-$8.69M$153.61M$119.54M$226.08M7 Day Performance3.06%-2.00%-1.83%-1.04%1 Month Performance-27.64%-7.46%-3.60%1.04%1 Year Performance-85.25%31.82%31.91%26.28% Quoin Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QNRXQuoin Pharmaceuticals2.236 of 5 stars$0.63+0.6%$4.00+535.3%-84.9%$3.18MN/A-0.164Negative NewsGap DownLYRALyra Therapeutics3.3367 of 5 stars$0.19+5.1%$4.50+2,305.1%-94.1%$12.25M$1.56M0.0050Analyst RevisionNews CoverageQTIQT ImagingN/A$0.54-5.8%N/AN/A$11.72MN/A0.00N/ANews CoveragePositive NewsPAVMPAVmed3.9986 of 5 stars$1.03flat$21.00+1,938.8%-68.7%$11.40M$2.45M-0.2490PETVPetVivoN/A$0.53+12.5%N/A-33.7%$10.90M$970,000.00-0.9820LUCYInnovative Eyewear2.4529 of 5 stars$6.70-2.0%$20.00+198.5%-21.4%$10.52M$1.15M-0.719Positive NewsICUSeaStar Medical0.2875 of 5 stars$2.18+1.4%N/A-82.8%$9.72MN/A0.002Gap UpSTRRStar Equity1.8155 of 5 stars$2.94-0.7%N/A-43.6%$9.50M$45.78M0.00171News CoverageGap UpTTOOT2 Biosystems2.4558 of 5 stars$0.44-4.7%$5.00+1,036.1%-88.3%$9.26M$7.19M0.00180PXDTPixie Dust Technologies1.9826 of 5 stars$0.58flat$5.21+798.3%N/A$8.63M$6.30M0.0078Upcoming EarningsNURONeuroMetrix0.5208 of 5 stars$4.16-4.1%N/A+11.5%$8.49M$5.90M0.0020Analyst ForecastNews CoverageGap Down Related Companies and Tools Related Companies LYRA Competitors QTI Competitors PAVM Competitors PETV Competitors LUCY Competitors ICU Competitors STRR Competitors TTOO Competitors PXDT Competitors NURO Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:QNRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Quoin Pharmaceuticals, Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Quoin Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
